Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Oruka Therapeutics ( (ORKA) ) is now available.
On April 28, 2026, Oruka Therapeutics entered into an underwriting agreement with a syndicate of investment banks to offer 9,660,000 shares of common stock at $72.50 per share, including a 30‑day option for underwriters to buy up to 1,449,000 additional shares. The offering, conducted under an effective shelf registration statement, closed on April 30, 2026, when the company completed the sale and issuance of 9,660,000 shares and agreed to customary indemnification provisions for the underwriters.
In a related update on recent developments, Oruka reported that it estimated cash, cash equivalents, and investments of approximately $496 million as of March 31, 2026, based on preliminary, unaudited financial data. The company emphasized that these figures were subject to revision upon completion of its accounting close, had not been reviewed or audited by its independent registered public accounting firm, and might not reflect final first‑quarter 2026 results.
The most recent analyst rating on (ORKA) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on Oruka Therapeutics stock, see the ORKA Stock Forecast page.
Spark’s Take on ORKA Stock
According to Spark, TipRanks’ AI Analyst, ORKA is a Neutral.
The score is held back primarily by no revenue, widening losses, and accelerating cash burn, partially offset by a strong, low-debt balance sheet. Technicals are supportive with strong trend/momentum (though overbought), and a positive Phase 2 clinical update provides a meaningful near-term fundamental boost, while valuation remains unattractive/unclear due to negative earnings and no dividend.
To see Spark’s full report on ORKA stock, click here.
More about Oruka Therapeutics
Oruka Therapeutics operates in the biopharmaceutical sector, focusing on the development of therapeutic products, and is financed through public equity markets. The company maintains significant liquidity to support its research and development activities, with hundreds of millions of dollars in cash, cash equivalents, and investments as of the end of the first quarter of 2026.
Average Trading Volume: 1,028,875
Technical Sentiment Signal: Buy
Current Market Cap: $3.42B
For a thorough assessment of ORKA stock, go to TipRanks’ Stock Analysis page.